Literature DB >> 31796513

Building on the Promise of Cancer Vaccines for Solid Tumors.

Craig L Slingluff1.   

Abstract

A novel telomerase vaccine (INVAC-1) has been evaluated in a phase I clinical trial (n = 26). It induced CD8+ and CD4+ T-cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases.See related article by Teixeira et al., p. 588. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31796513      PMCID： PMC7002281          DOI： 10.1158/1078-0432.CCR-19-3206

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Telomerase maintains telomere structure in normal human cells.

Authors:  Kenkichi Masutomi; Evan Y Yu; Shilagardy Khurts; Ittai Ben-Porath; Jennifer L Currier; Geoffrey B Metz; Mary W Brooks; Shuichi Kaneko; Seishi Murakami; James A DeCaprio; Robert A Weinberg; Sheila A Stewart; William C Hahn
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

2.  A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.

Authors:  Luis Teixeira; Jacques Medioni; Julie Garibal; Olivier Adotevi; Ludovic Doucet; Marie-Agnès Dragon Durey; Zineb Ghrieb; Jean-Jacques Kiladjian; Mara Brizard; Caroline Laheurte; Maria Wehbe; Elodie Pliquet; Marie Escande; Rémy Defrance; Stephane Culine; Stephane Oudard; Simon Wain-Hobson; Valérie Doppler; Thierry Huet; Pierre Langlade-Demoyen
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

3.  Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Authors:  Magalie Dosset; Yann Godet; Charline Vauchy; Laurent Beziaud; Yu Chun Lone; Christine Sedlik; Christelle Liard; Emeline Levionnois; Bertrand Clerc; Federico Sandoval; Etienne Daguindau; Simon Wain-Hobson; Eric Tartour; Pierre Langlade-Demoyen; Christophe Borg; Olivier Adotévi
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

Review 4.  Telomerase based anticancer immunotherapy and vaccines approaches.

Authors:  Chahal Kailashiya; Hanjabam Barun Sharma; Jyotsna Kailashiya
Journal:  Vaccine       Date:  2017-10-13       Impact factor: 3.641

Review 5.  T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.

Authors:  Robert Sackstein; Tobias Schatton; Steven R Barthel
Journal:  Lab Invest       Date:  2017-03-27       Impact factor: 5.662
  5 in total
  2 in total

1.  In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters.

Authors:  Inken Salewski; Yvonne Saara Gladbach; Steffen Kuntoff; Nina Irmscher; Olga Hahn; Christian Junghanss; Claudia Maletzki
Journal:  J Transl Med       Date:  2020-10-21       Impact factor: 5.531

2.  Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer.

Authors:  Juris Jansons; Dace Skrastina; Alisa Kurlanda; Stefan Petkov; Darya Avdoshina; Yulia Kuzmenko; Olga Krotova; Olga Trofimova; Ilya Gordeychuk; Irina Sominskaya; Maria Isaguliants
Journal:  Microorganisms       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.